Active substance
Pimavanserin
- US FDA 6
- US price lines 1
- Safety 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NUPLAZID | EQ 10MG BASE | tablet · oral | ACADIA PHARMS INC | Prescription | 29 Apr 2016 |
| NUPLAZID | EQ 34MG BASE | capsule · oral | ACADIA PHARMS INC | Prescription | 28 Jun 2018 |
| NUPLAZID | EQ 17MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | ACADIA PHARMS INC | Discontinued | 29 Apr 2016 |
| PIMAVANSERIN | EQ 34MG BASE | capsule · oral | ZYDUS | Discontinued | 16 Jan 2024 |
| PIMAVANSERIN | EQ 10MG BASE | tablet · oral | ZYDUS | Discontinued | 16 Jan 2024 |
| PIMAVANSERIN | EQ 34MG BASE | capsule · oral | MSN | Discontinued | 16 Jan 2024 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | NUPLAZID 34 MG CAPSULE | $170.496 | per EA | 18 Mar 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 27 Apr 2026 NUPLAZID — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 27 Apr 2026 NUPLAZID — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.